Enovis Corporation ENOV
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About ENOV
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Enovis Corporation (NYSE: ENOV) is a U.S.-based medical technology company focused on orthopedic and rehabilitation solutions. The company develops, manufactures, and markets products used in injury prevention, pain management, reconstructive surgery, and patient rehabilitation. Enovis operates primarily within the global musculoskeletal healthcare industry, serving hospitals, ambulatory surgery centers, orthopedic surgeons, physical therapists, prosthetists, and patients. Its core revenue drivers include orthopedic reconstruction implants, surgical technologies, bracing and support products, rehabilitation systems, and customized prosthetic solutions.
The company traces its roots to Colfax Corporation, an industrial manufacturing business founded in 1995. Following a series of healthcare-focused acquisitions and strategic repositioning, Colfax separated from much of its industrial portfolio and rebranded as Enovis Corporation in 2022 to reflect its concentration on medical technology. Enovis has since emphasized innovation in orthopedic reconstruction and patient mobility, positioning itself as a growth-oriented medtech company with integrated procedural and post-operative care capabilities.
Business Operations
Enovis primarily operates through two major business segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment includes orthopedic bracing, rehabilitation equipment, compression garments, bone growth stimulation devices, and recovery technologies sold under brands such as DonJoy, Aircast, and DJO. The Reconstructive segment focuses on surgical implant systems for hips, knees, shoulders, and foot-and-ankle procedures, alongside enabling technologies including robotics and surgical planning systems. Revenue is generated through direct product sales, distributor networks, and long-term relationships with healthcare providers globally.
The company maintains operations across North America, Europe, Asia-Pacific, and Latin America, supported by manufacturing facilities, research centers, and commercial offices. Enovis controls a portfolio of proprietary technologies related to orthopedic implants, motion therapy, and patient-specific surgical solutions. Key subsidiaries and acquired businesses include DJO Global, LimaCorporate, and various orthopedic technology platforms integrated into its reconstructive portfolio. The acquisition of LimaCorporate significantly expanded Enovis’s capabilities in joint reconstruction and advanced surgical technologies, including patient-specific implants and smart orthopedic systems.
Strategic Position & Investments
Enovis has pursued a strategy centered on becoming a scaled orthopedic and rehabilitation technology platform with differentiated procedural solutions. The company has invested heavily in higher-growth reconstructive markets, digital surgical technologies, and integrated patient care systems. A major strategic initiative has been the expansion of its reconstructive segment through acquisitions, product development, and surgeon-focused innovation. The acquisition of LimaCorporate represented one of the company’s most significant recent investments, strengthening its position in extremities, revision implants, and 3D-printed orthopedic technologies.
The company continues to emphasize innovation in areas such as robotics-assisted surgery, patient-specific implants, and digital rehabilitation tools. Enovis has also focused on operational efficiency and cross-selling opportunities between its rehabilitation and surgical product portfolios. Its strategy combines recurring rehabilitation demand with higher-growth reconstructive procedures, aiming to create continuity across the orthopedic patient care pathway. Public filings and investor materials consistently identify procedural orthopedics, global expansion, and technology-enabled care as central components of the company’s long-term growth strategy.
Geographic Footprint
Enovis is headquartered in Wilmington, Delaware, and maintains a substantial commercial and operational presence across North America, Europe, Asia-Pacific, and Latin America. The United States remains its largest market, supported by broad hospital and orthopedic clinic relationships. Internationally, the company has expanded through acquisitions, distributor partnerships, and localized manufacturing and sales infrastructure.
The acquisition of LimaCorporate, which has significant operations in Italy and broader European markets, increased Enovis’s presence across continental Europe and enhanced its international implant business. The company markets products in more than 100 countries through a combination of direct sales teams and third-party distributors. Its global operational footprint supports both developed healthcare systems and selected emerging markets where orthopedic procedure volumes are increasing.
Leadership & Governance
Enovis is led by an executive team with backgrounds in medical technology, orthopedic devices, healthcare operations, and industrial management. The company’s leadership strategy emphasizes innovation-driven growth, operational execution, and portfolio integration across rehabilitation and reconstructive care. Governance practices are outlined in annual filings and corporate governance disclosures, with oversight provided by an independent board of directors.
Key executives include:
- Matthew L. Trerotola – President and Chief Executive Officer
- Mark F. Williams – Senior Vice President and Chief Financial Officer
- Ben Berry – President, Reconstruction
- Damian Schmelzer – President, Prevention & Recovery
- Tracey V. Joubert – Senior Vice President, General Counsel and Secretary
The leadership team has consistently communicated a strategic vision focused on expanding Enovis into a leading global orthopedic technology platform through disciplined acquisitions, product innovation, and increased surgeon engagement. Public disclosures, including SEC filings and investor presentations, indicate continued prioritization of reconstructive growth, international expansion, and operational integration following major acquisitions.